265 related articles for article (PubMed ID: 22761788)
81. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients.
Clark RA; Watanabe R; Teague JE; Schlapbach C; Tawa MC; Adams N; Dorosario AA; Chaney KS; Cutler CS; Leboeuf NR; Carter JB; Fisher DC; Kupper TS
Sci Transl Med; 2012 Jan; 4(117):117ra7. PubMed ID: 22261031
[TBL] [Abstract][Full Text] [Related]
82. Antimouse CD52 monoclonal antibody inhibits established spontaneous colitis in IL-10-deficient mice.
Zhu WM; Li Y; Yu C; Li N; Li JS
Inflamm Bowel Dis; 2011 Jul; 17(7):E72-3. PubMed ID: 21538714
[No Abstract] [Full Text] [Related]
83. Definition of the variables affecting efficacy of immunodepletion ex vivo of peripheral blood progenitor cell grafts by alemtuzumab (Campath in the bag).
Novitzky N; Davison G; Abdulla R; Mowla S
Biol Blood Marrow Transplant; 2013 Dec; 19(12):1753-9. PubMed ID: 24120379
[TBL] [Abstract][Full Text] [Related]
84. Lowering the alemtuzumab dose in reduced intensity conditioning allogeneic hematopoietic cell transplantation is associated with a favorable early intense natural killer cell recovery.
Gärtner F; Hieke S; Finke J; Bertz H
Cytotherapy; 2013 Oct; 15(10):1237-44. PubMed ID: 23993297
[TBL] [Abstract][Full Text] [Related]
85. Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H.
Brett S; Baxter G; Cooper H; Johnston JM; Tite J; Rapson N
Immunology; 1996 May; 88(1):13-9. PubMed ID: 8707338
[TBL] [Abstract][Full Text] [Related]
86. Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis.
Gross CC; Ahmetspahic D; Ruck T; Schulte-Mecklenbeck A; Schwarte K; Jörgens S; Scheu S; Windhagen S; Graefe B; Melzer N; Klotz L; Arolt V; Wiendl H; Meuth SG; Alferink J
Neurol Neuroimmunol Neuroinflamm; 2016 Dec; 3(6):e289. PubMed ID: 27766281
[TBL] [Abstract][Full Text] [Related]
87. Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD 34+ cells and tumor cells of patients with chronic B-cell lymphoproliferative diseases.
Klabusay M; Sukova V; Coupek P; Brychtova Y; Mayer J
Cytometry B Clin Cytom; 2007 Sep; 72(5):363-70. PubMed ID: 17428002
[TBL] [Abstract][Full Text] [Related]
88. Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphoma.
Dunleavy K; Wilson WH
Leuk Lymphoma; 2010 Sep; 51(9):1583-4. PubMed ID: 20795788
[No Abstract] [Full Text] [Related]
89. Alemtuzumab therapy in B-cell lymphoproliferative disorders.
Moreton P; Hillmen P
Semin Oncol; 2003 Aug; 30(4):493-501. PubMed ID: 12939718
[TBL] [Abstract][Full Text] [Related]
90. CD52 expression in mantle cell lymphoma.
Bass AJ; Gong J; Nelson R; Rizzieri DA
Leuk Lymphoma; 2002 Feb; 43(2):339-42. PubMed ID: 11999566
[TBL] [Abstract][Full Text] [Related]
91. Targeting CD52 does not affect murine neuron and microglia function.
Ellwardt E; Vogelaar CF; Maldet C; Schmaul S; Bittner S; Luchtman D
Eur J Pharmacol; 2020 Mar; 871():172923. PubMed ID: 31962100
[TBL] [Abstract][Full Text] [Related]
92. Alemtuzumab depletes dendritic cells more effectively in blood than in skin: a pilot study in patients with chronic lymphocytic leukemia.
Auffermann-Gretzinger S; Eger L; Schetelig J; Bornhäuser M; Heidenreich F; Ehninger G
Transplantation; 2007 May; 83(9):1268-72. PubMed ID: 17496545
[TBL] [Abstract][Full Text] [Related]
93. Different mechanisms of Campath-1H-mediated depletion for CD4 and CD8 T cells in peripheral blood.
Lowenstein H; Shah A; Chant A; Khan A
Transpl Int; 2006 Nov; 19(11):927-36. PubMed ID: 17018129
[TBL] [Abstract][Full Text] [Related]
94. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
Nabhan C; Patton D; Gordon LI; Riley MB; Kuzel T; Tallman MS; Rosen ST
Leuk Lymphoma; 2004 Nov; 45(11):2269-73. PubMed ID: 15512816
[TBL] [Abstract][Full Text] [Related]
95. Cd52, known as a major maturation-associated sperm membrane antigen secreted from the epididymis, is not required for fertilization in the mouse.
Yamaguchi R; Yamagata K; Hasuwa H; Inano E; Ikawa M; Okabe M
Genes Cells; 2008 Aug; 13(8):851-61. PubMed ID: 18782223
[TBL] [Abstract][Full Text] [Related]
96. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia.
Lundin J; Porwit-MacDonald A; Rossmann ED; Karlsson C; Edman P; Rezvany MR; Kimby E; Osterborg A; Mellstedt H
Leukemia; 2004 Mar; 18(3):484-90. PubMed ID: 14749699
[TBL] [Abstract][Full Text] [Related]
97. CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies.
Geissinger E; Bonzheim I; Roth S; Rosenwald A; Müller-Hermelink HK; Rüdiger T
Leuk Lymphoma; 2009 Jun; 50(6):1010-6. PubMed ID: 19479612
[TBL] [Abstract][Full Text] [Related]
98. Synthesis and glycosylation of CD52, the major 'maturation-associated' antigen of rat spermatozoa, in the cauda epididymidis.
Derr P; Yeung CH; Cooper TG; Kirchhoff C
Reproduction; 2001 Mar; 121(3):435-46. PubMed ID: 11226070
[TBL] [Abstract][Full Text] [Related]
99. Preclinical pharmacology and toxicology evaluation of an anti-CD52 monoclonal antibody produced by perfusion fermentation process.
Wang Y; Zheng C; Zhuang C; Fu Q; Qin J; Zhang B; Bian Y; Qi N; Zhu J
J Ind Microbiol Biotechnol; 2021 Dec; 48(9-10):. PubMed ID: 34669957
[TBL] [Abstract][Full Text] [Related]
100. T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10.
Bandala-Sanchez E; Zhang Y; Reinwald S; Dromey JA; Lee BH; Qian J; Böhmer RM; Harrison LC
Nat Immunol; 2013 Jul; 14(7):741-8. PubMed ID: 23685786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
